ABLIM1 and cholangiocarcinoma: Specifically, the ABLIM1 expression in CCA was upregulated by 1.92-fold compared to CCA NATs (p < 0.001), 3.10-fold compared to HCC NATs (p < 0.0001), 4.83-fold compared to HCC (p < 0.0001), 4.72-fold compared to CRLM (p < 0.0001) and 5.20-fold compared to PCLM (p < 0.0001).